Zepbound (tirzepatide)
A preview of the mention intelligence report we deliver for $3,250. It shows who is talking about the drug and how much, and holds back what they are saying.
- Sponsor
- Eli Lilly and Company
- Window
- The 12 months to Oct 22, 2026, unless a source says otherwise
- Same molecule as
- Mounjaro
Key takeaways
Brand counts mentions that name Zepbound.
Molecule counts mentions of tirzepatide, which apply to Mounjaro too, so they are never credited to Zepbound alone.
- Molecule
Research talks about the molecule, not the brand. In the past 12 months, 1,405 PubMed papers named tirzepatide in their title or abstract. Only 22 named Zepbound, and 54 named Mounjaro.
- Molecule
88 companies besides Lilly named it in SEC filings. Zepbound or tirzepatide appears in 291 SEC filings from 89 companies. Lilly filed 10 of them.
- Brand
U.S. search interest hit a five-year high in January. Google searches for Zepbound peaked the week of Jan 4, 2026.
More takeaways in the full report, including which claims are spreading fastest and where the tone has turned.
Volume by channel
How much is being said about the drug, and where.
291
SEC filings naming Zepbound or tirzepatide
1,405
PubMed papers naming tirzepatide in the title or abstract
128
Preprints mentioning tirzepatide
Sources: SEC EDGAR full-text search, PubMed, Europe PMC
In the full report: volume month by month for each channel, including news, social media, and podcast and video transcripts, with what caused each spike.
Who is talking
The companies, journals, outlets, and communities that mention the drug most.
The most frequent SEC filer isn’t Lilly. MetaVia named Zepbound or tirzepatide in 19 filings over the past year, nearly twice as many as Lilly’s 10. Obesity developers, telehealth companies, and Novo Nordisk all appear in the list.
On Reddit, the conversation has its own home. In our sample of 1,762 posts and videos from YouTube, X, and Reddit, collected through Jun 28, 2026, the largest single community was r/Zepbound.
Sources: SEC EDGAR full-text search; Watchtower’s YouTube, X, and Reddit sample
In the full report: every company that mentioned the drug in an SEC filing and why, the journals publishing most on it, the news outlets covering it, and the most active creators and communities.
Themes and claims
What is being said about efficacy, safety, access, and pricing, and who is saying it.
In the full report: the leading themes in research, investor filings, news, and social media, the specific claims behind each, who is making them, and which are backed by a source you can check.
Tone
Positive, negative, and neutral coverage, shown with example quotes rather than scores alone.
In the full report: tone by channel and month, the quotes behind it, and the moments when it shifted.
Notable mentions
The articles, papers, and posts that mattered most, each linked.
- Molecule
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes, New England Journal of Medicine. Cited 225 times so far.
In the full report: the most significant articles, papers, filings, and posts of the past 12 months, with why each one matters.
Get the full mention report on Zepbound, or any other drug.
Every section above, complete, with every mention linked to its source and checked by an analyst. Delivered in 3 business days.
This sample was assembled from public records for illustration. It is not a customer deliverable. Social media and news counts come from a sample, not a count of every mention anywhere.